Radnostix, Inc (INIS) Fair Value & Analysis

Healthcare · US · Market cap $37.0M

Below-average quality, and screening another 50% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case ($0.0400). The favourable scenario is already priced in.
• Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range ($0.0200 to $0.0400) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 24, 2026.

How to read this chart

60‑month range $0.0270 – $0.2799 · fair‑value band $0.0200 – $0.0400 · the $0.0600 price screens above the $0.0300 fair value. Dashed = 300-day average. As of Jun 24, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Radnostix, Inc (INIS) currently trades at $0.0600, while our model-based Fair Value estimate is $0.0300, implying the stock looks roughly 50.0% overvalued today. The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Radnostix, Inc generated revenue of $12.2M at a net margin of -17.6%. Revenue declined 26.6% year over year. It earns a return on equity of -61.4%. Fundamentals as of Jun 24, 2026

Our scenario range runs from $0.0200 (bear case) to $0.0400 (bull case); at $0.0600, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 45% below its 52-week high and 20% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -50%, INIS screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally.

Full company description

Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. It operates through five segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The Theranostics Products segment produces and distributes Iodine-131 generic drug product and various isotopically pure radiochemicals for medical, industrial, and research applications. The Cobalt Products segment produces cobalt-60 products and services, the fabrication of cobalt-60 sealed sources for radiation therapy, industrial and medical applications, and recycling of expended cobalt-60 sources. The Calibration & Reference Products segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry. This segment also offers flood sources, dose calibrators, cylinder phantoms, rod sources, line sources, flexible and rigid rulers, spot markers, pen point markers, and various specialty design items. The Medical Devices segment develops EasyFill Automated Capsule System, a robotic lab device. The Fluorine Products segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility. The company sells its products directly to end users and distributors. The company was formerly known as International Isotopes Inc. and changed its name to Radnostix, Inc. in December 2025. Radnostix, Inc. was incorporated in 1995 and is headquartered in Idaho Falls, Idaho.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Radnostix, Inc reported revenue of $13.1M in FY2025 versus $9.7M in FY2021, a compound +7.8%/yr. Reported net income was −$908K in FY2025.

INIS screens 50% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 623 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Insider activity: 45/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.